$1.33
+1.9%Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
Wall Street analysts project that HCAT stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 2.25, with estimates ranging from a low of 1.75 to a high of 3.00.
The consensus 1-year price target stands at 2.25, with estimates ranging from a low of 1.75 to a high of 3.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Declining expectations indicate headwindsโinvestigate whether temporary or structural issues.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Moderate uncertainty in forecastsโtypical for companies with evolving business models.
Positive analyst consensus with strong growth expectations and forecast confidence.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Moderate uncertainty in forecastsโtypical for companies with evolving business models.
Generally favorable outlook with reasonable growth prospects and analyst support.
Significant contraction projectedโmajor business challenges or industry disruption likely.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Significant contraction projectedโmajor business challenges or industry disruption likely.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Generally favorable outlook with reasonable growth prospects and analyst support.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
During the last 12 months, insiders have sold $341K worth of HCAT shares, with no buying activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
0
0.00
+0
+$0
0
0.00
75.4K
200.68K
-201K
-$201K
0
0.00
40.8K
140.57K
-141K
-$141K
No buying activity
Larson-Green Julie
Director
$128K
Landry Benjamin
Officer: General Counsel
$127K
Burton Daniel D.
Director, Officer: Chief Executive Officer
$28K
Freeman Kevin Lee
Officer: Chief Commercial Officer
$15K
Lesueur Daniel
Officer: Chief Operating Officer
$12K
Strong bearish signal with $341K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Continue your HCAT research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.